articleTop 1% cited

Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide

Clinical Cancer Research · 2004 · Vol. 10(6) · pp. 1871–1874

Monika E. Hegi✉(Molecular Oncology (United States))Annie-Claire DiserensSophie GodardPierre-Yves Dietrich(University Hospital of Geneva)Luca Regli(University of Lausanne)Sandrine OstermannPhilippe Otten(University of Fribourg)Guy van Melle(Institute of Social and Preventive Medicine)Nicolas de Tribolet(University of Lausanne)Roger Stupp

View via DOI Publisher page

Abstract

This prospective clinical trial identifies MGMT-methylation status as an independent predictor for glioblastoma patients treated with a methylating agent. The association of the epigenetic inactivation of the DNA repair gene MGMT with better outcome in this homogenous cohort may have important implications for the design of future trials and supports efforts to deplete MGMT by O-6-benzylguanine, a noncytotoxic substrate of this enzyme.

Glioma Diagnosis and Treatment Epigenetics and DNA Methylation Brain Metastases and TreatmentTemozolomideMethyltransferaseMethylationO-6-methylguanine-DNA methyltransferaseDNA methylationCancer researchGlioblastomaDNA methyltransferasePromoterMedicine

MeSH terms

TemozolomideAdultAgedBiopsyBrain NeoplasmsCombined Modality TherapyDacarbazineFemaleGlioblastomaHumansMaleMiddle AgedPredictive Value of TestsPromoter Regions, GeneticTime Factors

Citations

788

FWCI

20.67

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial